« Back
Seattle Genetics to Present at Upcoming Investor Conferences

BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 1, 2017-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from the Seattle Genetics website at www.seattlegenetics.com in the Investors and News section.

Cowen and Company 37th Annual Health Care Conference
Wednesday, March 8, 10:40 a.m. Eastern Time, Boston

Barclays Global Healthcare Conference 2017
Wednesday, March 15, 10:45 a.m. Eastern Time, Miami

About Seattle Genetics

Seattle Genetics is an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer. The company’s industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. ADCETRIS® (brentuximab vedotin), the company’s lead product, in collaboration with Takeda Pharmaceutical Company Limited, is the first in a new class of ADCs and is commercially available globally in 66 countries for relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics is also advancing vadastuximab talirine (SGN-CD33A; 33A), an ADC in a phase 3 trial for acute myeloid leukemia. Headquartered in Bothell, Washington, Seattle Genetics has a robust pipeline of innovative therapies for blood-related cancers and solid tumors designed to address significant unmet medical needs and improve treatment outcomes for patients. The company has collaborations for its proprietary ADC technology with a number of companies including AbbVie, Astellas, Bayer, Celldex, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.

Source: Seattle Genetics, Inc.

Seattle Genetics, Inc.
Investors
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com
or
Media
Brandi Robinson, 425-527-2910
brobinson@seagen.com